drugset / Trial / NCT05092269
A Long-term Extension Study of Ustekinumab in Pediatric Participants
NaSingle-groupOpen-labelOther
Summary
The purpose of this study is to collect long-term safety data of subcutaneous (SC) ustekinumab
Timeline
- Start
- 2021-10-18
- Primary completion
- 2027-09-29
- Completion
- 2028-03-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ustekinumab | Monoclonal antibody | — | Subcutaneous |